Literature DB >> 22210944

Central nervous system relapses in 3 dogs with B-cell lymphoma.

Kyoung-Won Seo1, Ul-Soo Choi, Jong-Bok Lee, Mi-In Kim, Ye-In Oh, Jin-Young Chung, Sang-Koo Lee, Cheol-Yong Hwang, Hwa-Young Youn.   

Abstract

This report describes cases of central nervous system (CNS) relapse that occurred during chemotherapy in 3 dogs with lymphoma. Diagnosis was made by a combination of clinical signs and cytology of cerebrospinal fluid. The suspected risk factors, clinical features common to the 3 dogs, and treatment options are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210944      PMCID: PMC3119244     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  22 in total

1.  Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.

Authors:  Laura D Garrett; Douglas H Thamm; Ruthanne Chun; Robert Dudley; David M Vail
Journal:  J Vet Intern Med       Date:  2002 Nov-Dec       Impact factor: 3.333

2.  Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.

Authors:  S L Chua; J F Seymour; J Streater; M M Wolf; E H Januszewicz; H M Prince
Journal:  Leuk Lymphoma       Date:  2002-09

3.  Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

Authors:  P A Bunn; P S Schein; P M Banks; V T DeVita
Journal:  Blood       Date:  1976-01       Impact factor: 22.113

4.  Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients.

Authors:  E L Bollen; R E Brouwer; S Hamers; J Hermans; M Kluin; S U Sankatsing; R V A-Tjak; M V Charvat; J C Kluin-Nelemans
Journal:  Arch Neurol       Date:  1997-07

5.  Primary T-cell lymphoma of the central nervous system in a dog.

Authors:  S N Long; P E Johnston; T J Anderson
Journal:  J Am Vet Med Assoc       Date:  2001-03-01       Impact factor: 1.936

6.  Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Cancer       Date:  2002-08-01       Impact factor: 6.860

7.  Ataxia associated with lymphosarcoma in a dog.

Authors:  B K Lefbom; G A Parker
Journal:  J Am Vet Med Assoc       Date:  1995-10-01       Impact factor: 1.936

8.  Central nervous system lymphosarcoma in the dog.

Authors:  C G Couto; J Cullen; V Pedroia; J M Turrel
Journal:  J Am Vet Med Assoc       Date:  1984-04-01       Impact factor: 1.936

9.  Characteristic features of malignant lymphoma with central nervous system involvement.

Authors:  S Yoshida; K Morii; M Watanabe; T Saito
Journal:  Surg Neurol       Date:  2000-02

10.  Neurologic diseases associated with lymphosarcoma in ten dogs.

Authors:  A Rosin
Journal:  J Am Vet Med Assoc       Date:  1982-07-01       Impact factor: 1.936

View more
  2 in total

Review 1.  Beyond tradition and convention: benefits of non-traditional model organisms in cancer research.

Authors:  Rebecca M Harman; Sanjna P Das; Arianna P Bartlett; Gat Rauner; Leanne R Donahue; Gerlinde R Van de Walle
Journal:  Cancer Metastasis Rev       Date:  2020-10-28       Impact factor: 9.264

2.  Myoclonus and hypercalcemia in a dog with poorly differentiated lymphoproliferative neoplasia.

Authors:  Cassia H Z Hare; Joy Archer; Emilie Cloup; Marie-Aude Genain; Katherine Hughes; Katie E McCallum; Lisa Alves
Journal:  J Vet Intern Med       Date:  2018-12-18       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.